Stock Ticker

  • Loading stock data...

Ariad Pharmaceuticals, Inc.’s (NASDAQ:ARIA) CEO Steps Down

Ariad Pharmaceuticals, Inc.’s (NASDAQ:ARIA) CEO Harvey Berger has stepped down following calls for his dismissal by activist investor Alex Denner and his firm Sarissa Capital. There was a proxy fight between the company and the firm, and the cease fire seems to have cost Berger his job. Sarissa had called for the imminent retirement of […]

Bellicum Pharmaceuticals, Inc. and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Announce Reconstruction of License Agreement

Boston, MA 10/06/2014 (wallstreetpr) – According to reports, Bellicum Pharmaceuticals, Inc and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) have decided to announce the reconstruction of their license agreement for cell-signaling technology of ARIA. Insights of the matter: As part of the reconstruction process, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) will get $50 million in exchange for a fully paid […]

Four Stocks To Watch: Twenty-First Century Fox Inc (FOXA), QUALCOMM Inc. (QCOM), DryShips Inc. (DRYS), Ariad Pharmaceuticals Inc. (ARIA)

Boston, MA 10/04/2014 (wallstreetpr) – Leonardo DiCaprio, who is currently acting in Twenty-First Century Fox Inc (NASDAQ:FOXA)‘s most awaited movie ‘ The Revenant,’ has decided to take a break from acting career for some time. He was slated to work in Walter Isaacson’s biography of Steve Jobs. It is currently learnt that DiCaprio has said […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Director Alexander Denner Acquires Shares Indirectly

Boston, MA 08/21/2114 (wallstreetpr) – A global oncology company, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Director Alexander Denner had resorted to buying the company shares from the open market indirectly on August 15. The acquisition of shares was done for Sarissa Capital for two of its funds. Interestingly, the move comes in the wake of a Sell […]

Wall Street Takeaway: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), TherapeuticsMD Inc (NYSEMKT:TXMD), GoPro Inc (NASDAQ:GPRO)

Boston, MA 07/09/2014 (wallstreetpr) – The uncertainty in the biotech sector went down with Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) in the last session, putting it among the most active losers of the day. The stock slumped nearly 4 percent to $6.06 per share. The stock is down more than 11 percent this year. The U.S. biotech […]

In New Data, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) May Seek Expanded Treatment Scope For Iclusig

Boston, MA 06/02/2014 (wallstreetpr) – The cancer drug company Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has had its fair share of disappointments with its approved leukemia drug, Iclusig. From market suspension to halting of the study of the drug in newly-diagnosed patients, Ariad has seen it all but the company looks unbowed. At the weekend, Ariad released […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): Long Way To Go

Boston, MA 05/28/2014 (wallstreetpr) – Total revenue for the first quarter was $11.8 million, which includes $8 million as product revenue and $3.8 million as license revenue. Initiate growth Net product revenues including sales of Iclusig were $8.0 million, 25% year over year increase compared to $6.4 million during the same period last year. It includes […]

Monday Stock Roundup: Nokia Corporation (ADR) (NYSE:NOK), Pfizer Inc.(NYSE:PFE), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Boston, MA 03/03/2014 (wallstreetpr) – Nokia Corporation (ADR) (NYSE:NOK): The Supreme court in India starts hearing of the appeal dislodged by Nokia in efforts to overturn the running by a lower court in Delhi. The company is fighting tax crime allegations and its believes that the Delhi High Court issued “new conditions” for the transfer of […]

Ariad Pharmaceutical, Inc. (NASDAQ:ARIA) Still A “Sell” Despite Narrowing Of Its Q4 Loss

Boston, MA 02/28/2014 (wallstreetpr) – Ariad Pharmaceutical, Inc. (NASDAQ:ARIA) reported its fourth quarter results for 2013 in which earning per share beat Zacks estimated loss of 46 cents per share to come in at a loss of 40 cents a share, slightly higher than same quarter a year loss of 36 cents a share. TheStreet currently […]

What Investors Should Known About Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), American Realty Capital Properties Inc (NASDAQ:ARCP), Sunedison Inc (NYSE:SUNE)

Boston, MA 02/28/2014 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was last seen up more than 5 percent to $8.99. A volume of more than 23 million shares were traded in the last session, making the stock one the notable movers on Nasdaq. The stock escalated to $9.05 in the day and touched a low of […]

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): Expectations and Realities

Boston, MA 02/27/2014 (wallstreetpr) –  Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), after posting better than expected results at a time when it has come to known as controversial and volatile, is now attracting news analysts’ sentiments. Yet the company is also blowing its own trumpet and placing a lot of hopes in its recently re-launched leukemia drug […]

Investor Alert: Nokia Corporation (ADR) (NYSE:NOK), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Inovio Pharmaceuticals Inc (NYSEMKT:INO)

Boston, MA 02/26/2014 (wallstreetpr) – Nokia Corporation (ADR) (NYSE:NOK) eventually put rumors to rest, but somehow learnt that it can be very difficult to place a tight lid on what you are cooking in the tech industry. The devices which the company announced were not far from the rumors that had already hit the streets […]

On The Spotlight: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Yahoo! Inc. (NASDAQ:YHOO)

Boston, MA 02/25/2014 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) releases its fiscal 2013 fourth quarter early morning Tuesday, February 25. The company is expected to report earnings of (47 cents) per share. Revenue is expected to come in at $6.31 million. These are estimates issued by analysts tracking the stock. ARIA has a consensus “hold” […]

Stocks on the Spotlight: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Oi SA (ADR) (NYSE:OIBR), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Boston, MA 02/20/2014 (wallstreetpr) – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) could soon be without the services of its billionaire chairman Philip Frost if reports appearing on the media are true. It is reported that the entrepreneur might leave the Israel-based TEVA before his current terms expires next year. However, some other reports say that Mr. […]

Investor Digest: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Morgan Stanley (NYSE:MS), Yamana Gold Inc. (USA) (NYSE:AUY)

Boston, MA 02/20/2014 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): According to the latest 13F filings, Sarissa Capital managed by Alex Denner revealed holding about 12 million shares of ARIA common stock. Given that amount of common stock ownership, the hedge fund’s stake in the biotech company is roughly 6.2 percent. Mr. Denner has expansive understanding of […]